{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-033159","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.858823+00:00","generated_at":"2026-06-04T13:44:26.492573+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Coya Therapeutics reports FY2023 net loss of $8.0M; cash $32.6M plus $7.5M upfront from Dr. Reddy's","bullets":["Net loss improved to $8.0M in FY2023 from $12.2M in FY2022; R&D spend $5.5M, G&A $7.8M.","Cash and equivalents $32.6M at Dec 31, 2023; plus $7.5M upfront from Dr. Reddy's received Jan 2024.","Closed Jan 2023 IPO net $14.1M and Dec 2023 private placement net $24.0M.","Dr. Reddy's collaboration for COYA 302 in ALS: up to $733M milestones plus low-to-mid teens royalties.","IND for COYA 302 in ALS expected 2Q24; Ph.2 topline data targeted for 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-033159","json":"https://secwatch.observer/filing/0000950170-24-033159.json","markdown":"https://secwatch.observer/filing/0000950170-24-033159.md","text":"https://secwatch.observer/filing/0000950170-24-033159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000095017024033159/0000950170-24-033159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000095017024033159/coya-20240319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:44:26.492573+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"920237ff3dcc9b91acc8508e3d275bdc421b31b7","claim":"Coya Therapeutics, Inc. reported financial results for the year ended December 31, 2023.","evidence_excerpt":"On March 19, 2024, Coya Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835022/000095017024033159/0000950170-24-033159-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}